Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tracon Pharma (TCON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,364
  • Shares Outstanding, K 29,871
  • Annual Sales, $ 8,760 K
  • Annual Income, $ -19,100 K
  • 36-Month Beta 2.95
  • Price/Sales 8.19
  • Price/Cash Flow N/A
  • Price/Book 1.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.46
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -2.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.76 +35.53%
on 01/28/19
1.17 -11.97%
on 02/07/19
-0.01 (-0.96%)
since 01/22/19
3-Month
0.50 +106.00%
on 12/26/18
1.49 -30.87%
on 11/30/18
-0.19 (-15.57%)
since 11/21/18
52-Week
0.50 +106.00%
on 12/26/18
3.20 -67.81%
on 06/15/18
-1.07 (-50.95%)
since 02/22/18

Most Recent Stories

More News
TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration,...

TCON : 1.03 (-1.90%)
TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma

Three Confirmed Partial Responses (20%) by RECIST and > 50% Reductions of Alpha Fetoprotein in Half of Patients Treated to Date with Combination of TRC105 and Nexavar(R)

TCON : 1.03 (-1.90%)
Biotech Stocks on the Move

HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold...

TCON : 1.03 (-1.90%)
TYME : 2.99 (+1.36%)
ZIOP : 3.03 (+6.69%)
DCTH : 0.2890 (+1.40%)
MNKD : 1.56 (+7.59%)
Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PPL Corporation (NYSE:PPL),...

CUI : 1.42 (unch)
TCON : 1.03 (-1.90%)
ORGS : 5.20 (unch)
INSG : 5.64 (+1.62%)
SGMS : 28.77 (+0.10%)
PPL : 31.64 (+0.70%)
Stocks to Watch Before The Opening Bell on December 27, 2018

CORAL GABLES, FL / ACCESSWIRE / December 27, 2018 / This year has been nothing short of exciting for , with swings occurring almost regularly. As sectors across all industries start to find methods to...

WATT : 10.93 (+2.73%)
PHGI.CN : 0.880 (+4.76%)
TCON : 1.03 (-1.90%)
PHGRF : 0.6715 (+4.92%)
ANFI : 1.00 (+1.01%)
TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo(R) for Treatment of Non-Small Cell Lung Cancer

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration...

TCON : 1.03 (-1.90%)
TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today announced that TRACON...

TCON : 1.03 (-1.90%)
TRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs

Due to the United States stock markets being closed on Wednesday, December 5, 2018, for the national day of mourning due to the passing of President George H. W. Bush, TRACON Pharmaceuticals (Nasdaq: TCON),...

TCON : 1.03 (-1.90%)
TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and I-Mab Biopharma ("I-Mab"),...

TCON : 1.03 (-1.90%)
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and I-Mab Biopharma ("I-Mab"),...

TCON : 1.03 (-1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade TCON with:

Business Summary

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California....

See More

Key Turning Points

2nd Resistance Point 1.07
1st Resistance Point 1.05
Last Price 1.03
1st Support Level 1.01
2nd Support Level 0.99

See More

52-Week High 3.20
Fibonacci 61.8% 2.17
Fibonacci 50% 1.85
Fibonacci 38.2% 1.53
Last Price 1.03
52-Week Low 0.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar